High survival rates in trial against severe COVID-19—related respiratory distress

Written by Alexander Marshall

Patients with severe COVID-19—related acute respiratory distress demonstrated an 83% survival rate following stem cell therapy. Compassionate use of a cell therapy product developed by clinical-stage cell therapy company Mesoblast (Melbourne, Australia) suggests that ventilator-dependent patients with COVID-19 had their survival rate increased to 83% from 12% following treatment with mesenchymal stem cells (MSCs). The patients had all developed moderate or severe acute respiratory distress syndrome (ARDS), which currently can only be managed with ventilator support and is often fatal. Want regular updates straight to your inbox? Become a member of RegMedNet here>> Patients were treated over a period of...

To view this content, please register now for access

It's completely free